米非司酮治疗子宫肌瘤合并贫血患者疗效观察  

Clinical Observation of Mifepristone for Treatment of Patients with Hysteromyoma and Intercurrent Anaemia

作　　者：王宝珍[1] 张颖[2] 郭晓凌[2] 王军[2] 

机构地区：[1]辉县市人民医院妇产科,辉县市453600 [2]郑州大学第三附属医院,郑州市450052

出　　处：《医药论坛杂志》2006年第23期26-27,共2页Journal of Medical Forum

摘　　要：目的探讨米非司酮在改善子宫肌瘤合并贫血患者情况中的作用。方法选择子宫肌瘤合并贫血患者65例,将其随机分为治疗组34例及对照组31例,治疗组每日给予速力菲片2片,同时口服米非司酮12.5mg/d,3个月。对照组每日口服速力菲片2片。3个月后检测血常规及肝肾功能。B超观察治疗前后肌瘤体积。结果治疗组血红蛋白量有了明显提高,由服药前的73.42g/L上升到服药后的113.90g/L,对照组由服药前的74.18g/L上升到服药后的82.24g/L,治疗组显著高于对照组(P<0.05);治疗组子宫肌瘤体积明显缩小,由服药前的146.20 cm3降至服药后的75.36 cm3,显著小于对照组(P<0.05);且治疗组未出现明显不良反应。结论小剂量米非司酮在缩小子宫肌瘤的同时改善贫血状态,可以作为术前用药,为手术创造条件。Objective To evaluate the effects of mifepristone for treatment of hysteromyoma and intercurrent anaemia. Methods 65 patients of hysteromyoma and intercurrent anaemia were clasified into two groups randomly, treatment group 34 cases and control group 31 cases. Mifepristone （ 12. 5 mg/d） and ferrous succinate（200mg/d） were performed with orally administration for 3 months in treatment group. Control group was only treated with ferrous succinate （200 mg/d） for 3 months. Blood routine, liver function and kidney function were detected in laboratory. Changes of size of uterine myoma were observed by B ultrasonic. Results After 3 months Hb in treatment group （73.42g/L to 113.90g/L） was significantly increased than that in control group （74. 18g/L to 82. 24g/L） （ P 〈 0. 05 ） ; the size of myoma deflated obviously in treatment group, smaller than in control group （ 146. 20cm^3 vs 75.36cm^ 3） （ P 〈 0. 05 ） ; we found no obvious side effect in treatment group. Conclusion Low- dose mifepristone can reduce the size of myoma and rectify anaemia. It can improve patients constitution as preocupation medicine.

关 键 词：米非司酮 子宫肌瘤 贫血 

分 类 号：R737.33[医药卫生—肿瘤]